Intellia Therapeutics Gets FDA Orphan Drug Designation for Acute Myeloid Leukemia Treatment
10 March 2022 - 8:53AM
Dow Jones News
By Kimberly Chin
Intellia Therapeutics Inc. said the U.S. Food and Drug
Administration has granted its acute myeloid leukemia treatment an
orphan drug designation.
NTLA-5001 is an autologous T-cell receptor therapy that targets
the Wilms' Tumor antigen, which is a common expression in acute
myeloid leukemia and other hematologic and solid tumors.
The treatment is currently being reviewed in a Phase 1/2a study
in adults who have a detectable sign of the disease and have
received standard first-line treatment, the clinical-stage genome
editing company said.
The FDA's designation is granted to drugs that are intended for
the treatment, diagnosis or prevention of rare diseases that can
affect fewer than 200,000 people in the U.S. Drugs that receive the
designation can qualify companies for certain tax credits,
prescription drug user-fee exemptions and a seven-year marketing
exclusivity once the drug is approved by the FDA.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
March 09, 2022 16:38 ET (21:38 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024